Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Gross Margin (2016 - 2025)

CorMedix's Gross Margin history spans 12 years, with the latest figure at 83.43% for Q4 2025.

  • For Q4 2025, Gross Margin fell 1280.0% year-over-year to 83.43%; the TTM value through Dec 2025 reached 88.46%, down 599.0%, while the annual FY2025 figure was 88.46%, 420.0% down from the prior year.
  • Gross Margin for Q4 2025 was 83.43% at CorMedix, down from 89.26% in the prior quarter.
  • Across five years, Gross Margin topped out at 8322.71% in Q1 2024 and bottomed at 4519.22% in Q2 2024.
  • The 4-year median for Gross Margin is 86.35% (2025), against an average of 294.77%.
  • The largest YoY upside for Gross Margin was 461453bps in 2025 against a maximum downside of -822680bps in 2025.
  • A 4-year view of Gross Margin shows it stood at 14.88% in 2021, then surged by 563bps to 98.63% in 2022, then decreased by -2bps to 96.24% in 2024, then dropped by -13bps to 83.43% in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Gross Margin are 83.43% (Q4 2025), 89.26% (Q3 2025), and 95.31% (Q2 2025).